Erasca (ERAS)
(Delayed Data from NSDQ)
$2.38 USD
+0.02 (0.85%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.37 -0.01 (-0.21%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Erasca, Inc. [ERAS]
Reports for Purchase
Showing records 1 - 4 ( 4 total )
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Naporafenib Leads MAPK Assault with Data in 2/4Q24; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress and Prioritization Refine MAPK Assault Strategy; Reit Buy and Lowering Our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Rich Catalyst Calendar Looks to Showcase an Assault on MAPK; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
An Oncogenic MAPK Assault on All Fronts; Initiating with a Buy Rating and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
|